# OnCo record medulloblastoma-group-3-4 (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/medulloblastoma-group-3-4/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "medulloblastoma-group-3-4" ;
  schema:name "Group 3 and group 4 medulloblastoma (non-WNT/non-SHH)"@en ;
  schema:alternateName "Non-WNT/non-SHH medulloblastoma"@en, "Group 3 medulloblastoma"@en, "Group 4 medulloblastoma"@en, "MYC-amplified medulloblastoma"@en ;
  schema:description "Group 3 and group 4 medulloblastoma are the two commonest forms of this cerebellar brain tumour and the ones without a druggable driver. Group 3 strikes young children, often with extra copies of MYC and spread through the spinal fluid; group 4 affects older boys. Both get surgery, craniospinal radiotherapy and chemotherapy; trials showed the radiation dose cannot be cut for young children."@en ;
  schema:url <https://onco.cc/cancers/medulloblastoma-group-3-4/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Medulloblastoma> ;
  schema:citation <https://en.wikipedia.org/wiki/Medulloblastoma>, <https://www.cancer.gov/types/brain/hp/child-cns-embryonal-treatment-pdq> ;
  onco:tag "subtype-page", "paediatric", "cns" ;
  onco:related <https://onco.cc/cancers/medulloblastoma-wnt/>, <https://onco.cc/cancers/medulloblastoma-shh/> ;
  onco:technologies <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/> ;
  onco:drugs <https://onco.cc/drugs/isotretinoin/> ;
  onco:institutions <https://onco.cc/institutions/childrens-oncology-group/>, <https://onco.cc/institutions/siop-europe/>, <https://onco.cc/institutions/st-jude/> ;
  onco:pathways <https://onco.cc/pathways/myc/> ;
  onco:terms <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/medulloblastoma-molecular-groups/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-who-2021-cns-louis-neuro-oncology-2021/>, <https://onco.cc/key-papers/paper-taylor-medulloblastoma-consensus-acta-neuropathol-2012/>, <https://onco.cc/key-papers/paper-cavalli-medulloblastoma-subtypes-cancer-cell-2017/>, <https://onco.cc/key-papers/paper-acns0332-leary-jama-oncol-2021/> ;
  onco:pipeline <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/ideas/idea-fund-proton-coverage-with-evidence/> ;
  onco:standardOfCare <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/lomustine/>, <https://onco.cc/trials/acns0331/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/thiotepa/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/drugs/irinotecan/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/technologies/survivorship-care-plan/> .